Eide, Per Kristian http://orcid.org/0000-0001-6881-9280
Lashkarivand, Aslan
Pripp, Are
Valnes, Lars Magnus
Hovd, Markus Herberg http://orcid.org/0000-0002-6077-0934
Ringstad, Geir http://orcid.org/0000-0003-0919-4510
Blennow, Kaj http://orcid.org/0000-0002-1890-4193
Zetterberg, Henrik http://orcid.org/0000-0003-3930-4354
Article History
Received: 19 November 2022
Accepted: 27 March 2023
First Online: 12 April 2023
Competing interests
: P.K.E. and G.R. are shareholders in BrainWideSolutions AS, Oslo, Norway, which is a holder of patent US 11,272,841. K.B. has served as a consultant on advisory boards or on data monitoring committees for Abcam, Axon, BioArctic, Biogen, and JOMDD/Shimadzu. Julius Clinical, Lilly, MagQu, Novartis, Ono Pharma, Pharmatrophix, Prothena, Roche Diagnostics, and Siemens Healthineers, and is a co-founder of Brain Biomarker Solutions in Gothenburg AB (BBS), which is a part of the GU Ventures Incubator Program, outside the work presented in this paper. H.Z. has served on scientific advisory boards and/or as a consultant for Abbvie, Acumen, Alector, ALZPath, Annexon, Apellis, Artery Therapeutics, AZTherapies, CogRx, Denali, Eisai, Nervgen, Novo Nordisk, Passage Bio, Pinteon Therapeutics, Red Abbey Labs, reMYND, Roche, Samumed, Siemens Healthineers, Triplet Therapeutics, and Wave, has given lectures in symposia sponsored by Cellectricon, Fujirebio, Alzecure, Biogen, and Roche, and is a co-founder of Brain Biomarker Solutions in Gothenburg AB (BBS), which is a part of the GU Ventures Incubator Program (outside submitted work). The remaining authors declare no competing interests.